PRESS RELEASE
Nov 15, 2024
Long-Term, BioStem Technologies Still A Promising Growth Stock
Nov 15, 2024
BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript
Nov 12, 2024
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
Oct 29, 2024
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
Oct 28, 2024
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Oct 23, 2024
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
Oct 17, 2024
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
Oct 15, 2024
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
Oct 02, 2024
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
Sep 30, 2024
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting